Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. shareholders have greenlit the creation of preferred shares and a subsequent issuance tied to a debt-to-equity deal with the European Investment Bank, contingent on the completion of the transaction. Additionally, the shareholders approved a grant of restricted share units to CEO Amir Reichman as part of his 2023 long-term incentive plan. These strategic moves aim to strengthen the company’s financial structure and incentivize its top executive.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
